United Therapeutics (UTHR) general counsel Mahon sold 8,300 shares for $3.9M at an average $469.89 under a 10b5-1 plan
Insider transactions reported
Paul A Mahon (EVP & General Counsel at United Therapeutics Corporation, UTHR) reported that they sold 8,300 shares for $3.9M at an average $469.89, and acquired 8,300 shares at $146.03 on Jan 15, 2026. After these transactions the filing shows 36,781 shares held directly.
- Reporting person
- Mahon Paul A
- Role
- EVP & GENERAL COUNSEL
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | Exercise or conversion of a derivative (M) | Common Stock1 | +8,300 | $146.03 | $1.21M | 45,081 direct |
| Jan 15, 2026 | Open-market sale (S) | Common Stock1, 2, 3, ... | -8,300 | avg $469.89 | $3.9M | 36,781 direct |
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | Exercise or conversion of a derivative (M) | Stock OptionOn 8,300 Common Stock1 | -8,300 | - | - | 58,400 direct |
Holdings before and after
- Stock Option: 66,700 to 58,400 direct
Footnotes from the filing
- 1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
- 2. This transaction was executed in multiple trades at prices ranging from $467.815 to $468.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
- Exercise or conversion of a derivative:
- Code M marks the exercise or conversion of an option or other derivative under an exempt plan.
FAQ
What did Mahon report in this UTHR Form 4?
Paul A Mahon (EVP & General Counsel at United Therapeutics Corporation, UTHR) reported that they sold 8,300 shares for $3.9M at an average $469.89, and acquired 8,300 shares at $146.03 on Jan 15, 2026. After these transactions the filing shows 36,781 shares held directly.
How many UTHR shares does Mahon hold after this filing?
The filing shows 36,781 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this UTHR insider sale made under a 10b5-1 plan?
The filing's footnotes mention a Rule 10b5-1 trading plan. Such a plan sets the terms of future trades in advance.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for UTHR
Across the 5 sessions after earlier UTHR headlines, the stock closed higher 1 times and lower 4 times, with a median move of 1.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | UTHR | SPY |
|---|---|---|---|
| Jan 5, 2026 | United Therapeutics Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference | -1.4% | +0.7% |
| Nov 4, 2025 | United Therapeutics Corporation to Present at Upcoming Investor Conferences | -0.3% | -1.2% |
| Nov 3, 2025 | United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease | -1.5% | +0.2% |
| Oct 29, 2025 | United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results | +9.6% | +0.0% |
| Oct 20, 2025 | Wells Fargo initiated coverage on United Therapeutics with a new price target | -0.1% | +1.0% |
Earlier insider filings at UTHR
- Jan 13, 2026PRESIDENT AND COO Benkowitz Michael exercised 22,500 shares at a strike of $127.65 and sold $10,788,876 worth of shares (22,500 units at $479.51) (SEC Form 4)
- Jan 7, 2026PRESIDENT AND COO Benkowitz Michael exercised 14,625 shares at a strike of $117.76 and sold $7,127,877 worth of shares (14,625 units at $487.38) (SEC Form 4)
- Jan 7, 2026PRESIDENT AND COO Benkowitz Michael exercised 7,875 shares at a strike of $146.03 and sold $3,838,085 worth of shares (7,875 units at $487.38) (SEC Form 4)
- Jan 6, 2026Director Causey Christopher exercised 1,000 shares at a strike of $119.76 and sold $510,000 worth of shares (1,000 units at $510.00) (SEC Form 4)
- Jan 6, 2026Director Malcolm Jan sold $24,750 worth of shares (50 units at $495.01), decreasing direct ownership by 12% to 370 units (SEC Form 4)
Keep researching UTHR
- UTHR insider tradesEvery buy and sale reported by United Therapeutics Corporation officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- UTHR earnings historyPast United Therapeutics Corporation earnings releases, newest first.
- UTHR financial statementsRevenue, profit, cash flow and balance sheet from United Therapeutics Corporation's SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 1999
Follow UTHR and get a push notification the moment its next story breaks.